{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:44:52Z","timestamp":1777520692512,"version":"3.51.4"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Women's Dermatology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ijwd.2019.05.008","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T15:45:17Z","timestamp":1559922317000},"page":"372-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-na\u00efve and previously treated patients with pemphigus vulgaris after receiving rituximab"],"prefix":"10.1097","volume":"5","author":[{"given":"Hoorieh","family":"Alaeen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roja","family":"Toosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Balighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheil","family":"Tavakolpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Teimoupour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Daneshpazhooh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"5","key":"10.1016\/j.ijwd.2019.05.008_bb0005","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.05.008_bb0010","first-page":"135","article-title":"Longitudinal tracking of autoantibody levels in a pemphigus vulgaris patient: Support for a role of anti-desmoglein 1 autoantibodies as predictors of disease progression","volume":"16","author":"Abidi","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"10.1016\/j.ijwd.2019.05.008_bb0015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/exd.13106","article-title":"Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology","volume":"25","author":"Ahmed","year":"2016","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.05.008_bb0020","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2017.07.012","article-title":"Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab","volume":"77","author":"Albers","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijwd.2019.05.008_bb0025","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3389\/fimmu.2018.01190","article-title":"Non-desmoglein antibodies in patients with pemphigus vulgaris","volume":"9","author":"Amber","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.05.008_bb0030","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaad.2015.04.038","article-title":"The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis","volume":"73","author":"Atzmony","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.05.008_bb0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00403-018-1881-1","article-title":"Comparing early and late treatments with rituximab in pemphigus vulgaris: Which one is better?","volume":"311","author":"Balighi","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ijwd.2019.05.008_bb0040","doi-asserted-by":"crossref","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijwd.2019.05.008_bb0045","series-title":"Clinical cases in autoimmune blistering diseases. Basel, Switzerland","first-page":"51","article-title":"A 52-year-old man with cerebriform vegetating masses on the scalp","author":"Daneshpazhooh","year":"2015"},{"issue":"10","key":"10.1016\/j.ijwd.2019.05.008_bb0050","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1468-3083.2007.02254.x","article-title":"Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: Correlation with phenotype, severity, and disease activity","volume":"21","author":"Daneshpazhooh","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.05.008_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ced.12187","article-title":"Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris","volume":"39","author":"Daneshpazhooh","year":"2014","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.05.008_bb0060","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2015.10.051","article-title":"Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission","volume":"74","author":"Daneshpazhooh","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.05.008_bb0065","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jaad.2018.03.035","article-title":"Comparison of ethylenediaminetetraacetic acid-treated desmoglein ELISA and conventional desmoglein ELISA in the evaluation of pemphigus vulgaris in remission","volume":"79","author":"Daneshpazhooh","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.ijwd.2019.05.008_bb0070","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/ddg.13306","article-title":"Anagen hair loss, anti-desmoglein 1, and Pemphigus Disease Area Index: A significant relationship?","volume":"15","author":"Fard","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.ijwd.2019.05.008_bb0075","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4103\/0975-8844.143051","article-title":"Usefulness of desmoglein 1 and 3 in serodiagnosis of pemphigus vulgaris and its correlation with disease activity - ELISA study","volume":"6","author":"Gandhi","year":"2014","journal-title":"J Orofacial Sci"},{"issue":"4","key":"10.1016\/j.ijwd.2019.05.008_bb0080","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.05.008_bb0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores","volume":"139","author":"Hebert","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.05.008_bb0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/1523-1747.ep12460927","article-title":"Regional variation in the expression of pemphigus foliaceus, pemphigus erythematosus, and pemphigus vulgaris antigens in human skin","volume":"96","author":"Ioannides","year":"1991","journal-title":"J Invest Dermatol"},{"issue":"10083","key":"10.1016\/j.ijwd.2019.05.008_bb0095","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijwd.2019.05.008_bb0100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-2133.2012.10929.x","article-title":"Detection of antibodies against the non-calcium-dependent epitopes of desmoglein 3 in pemphigus vulgaris and their pathogenic significance","volume":"167","author":"Kamiya","year":"2012","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.05.008_bb0105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2013.02.011","article-title":"A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris","volume":"70","author":"Kamiya","year":"2013","journal-title":"J Dermatol Sci"},{"issue":"3","key":"10.1016\/j.ijwd.2019.05.008_bb0110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/0378-6323.25780","article-title":"Study of desmoglein 1 and 3 antibody levels in relation to disease severity in Indian patients with pemphigus","volume":"72","author":"Kumar","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.05.008_bb0115","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2340\/00015555-1961","article-title":"Correlation of conventional and conformational anti-desmoglein antibodies with phenotypes and disease activities in patients with pemphigus vulgaris","volume":"95","author":"Li","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ijwd.2019.05.008_bb0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.intimp.2019.02.037","article-title":"Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases","volume":"71","author":"Mahmoudi","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.05.008_bb0125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ejh.12839","article-title":"Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response","volume":"98","author":"Marangon","year":"2017","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.ijwd.2019.05.008_bb0130","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ijwd.2019.05.008_bb0135","first-page":"53","article-title":"Desmoglein ELISA in the diagnosis of pemphigus and its correlation with the severity of pemphigus vulgaris","volume":"8","author":"Mortazavi","year":"2009","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.05.008_bb0140","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijwd.2019.05.008_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: Recommendations by an international panel of experts","author":"Murrell","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.05.008_bb0150","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/08916934.2014.976629","article-title":"Detailed profiling of anti-desmoglein autoantibodies identifies anti-Dsg1 reactivity as a key driver of disease activity and clinical expression in pemphigus vulgaris","volume":"48","author":"Naseer","year":"2015","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.ijwd.2019.05.008_bb0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2340\/00015555-1666","article-title":"Clinical significance of anti-desmoglein-1 and -3 circulating autoantibodies in pemphigus patients measured by area index and intensity score","volume":"94","author":"Patsatsi","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.ijwd.2019.05.008_bb0160","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1365-4362.1995.tb04426.x","article-title":"Treatment-resistant pemphigus vegetans of the scalp","volume":"34","author":"Rackett","year":"1995","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.05.008_bb0165","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2011.12.019","article-title":"Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up","volume":"67","author":"Reguiai","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2019.05.008_bb0170","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.05.008_bb0175","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5114\/pdia.2017.71267","article-title":"Scalp involvement in pemphigus: A prognostic marker","volume":"35","author":"Sar-Pomian","year":"2018","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.ijwd.2019.05.008_bb0180","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-4632.2006.02593.x","article-title":"Evaluation of desmoglein enzyme-linked immunosorbent assay (ELISA) in Indian patients with pemphigus vulgaris","volume":"45","author":"Sharma","year":"2006","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.05.008_bb0185","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1046\/j.1523-1747.1998.00085.x","article-title":"Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1","volume":"110","author":"Shirakata","year":"1998","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.05.008_bb0190","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1684\/ejd.2015.2652","article-title":"The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris","volume":"25","author":"Sinistro","year":"2015","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ijwd.2019.05.008_bb0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review","volume":"54","author":"Tavakolpour","year":"2017","journal-title":"Int Immunopharmacol"}],"container-title":["International Journal of Women's Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352647519300498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352647519300498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T14:26:05Z","timestamp":1641565565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352647519300498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S2352647519300498"],"URL":"https:\/\/doi.org\/10.1016\/j.ijwd.2019.05.008","relation":{},"ISSN":["2352-6475"],"issn-type":[{"value":"2352-6475","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-na\u00efve and previously treated patients with pemphigus vulgaris after receiving rituximab","name":"articletitle","label":"Article Title"},{"value":"International Journal of Women's Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijwd.2019.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of Women's Dermatologic Society.","name":"copyright","label":"Copyright"}]}}